首页> 外国专利> Prodrugs of C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro biological activities, pharmacokinetics and antitumor activity

Prodrugs of C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro biological activities, pharmacokinetics and antitumor activity

机译:C-17-杂芳基甾体CYP17抑制剂/抗雄激素的前药:合成,体外生物学活性,药代动力学和抗肿瘤活性

摘要

Prodrugs of steroidal C-17 benzoazoles, pyrimidinoazoles (az-abenzoazoles) and diazines. Methods of synthesis are also described, whereby a prodrug group is substituted for a functional group at A ring portion of the ABC ring structure of the steroid. Suitable pro-drug groups include amino acid groups, succinate groups, phosphate groups, or sulfamate groups. The prodrugs of the disclosed compounds allow for improved oral bioavailability of the compounds that are inhibitors of human CYP 17 enzyme as well as potent antagonists of both wild type and mutant androgen receptors (AR). The compounds and the corresponding prodrugs are useful for the treatment of conditions such as human prostate cancer, breast cancer, and prostate hyperplasia.
机译:甾体C-17苯并恶唑,嘧啶并恶唑(az-abenzoazoles)和二嗪的前药。还描述了合成方法,其中前药基团取代了类固醇的ABC环结构的A环部分的官能团。合适的前药基团包括氨基酸基团,琥珀酸酯基团,磷酸基团或氨基磺酸酯基团。公开的化合物的前药使得作为人CYP 17酶抑制剂以及野生型和突变雄激素受体(AR)的有效拮抗剂的化合物的口服生物利用度得到改善。该化合物和相应的前药可用于治疗诸如人前列腺癌,乳腺癌和前列腺增生的病症。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号